PMID- 8122120 OWN - NLM STAT- MEDLINE DCOM- 19940405 LR - 20191023 IS - 0049-0172 (Print) IS - 0049-0172 (Linking) VI - 23 IP - 3 DP - 1993 Dec TI - Late-onset, seropositive, erosive rheumatoid arthritis. PG - 177-82 AB - This report describes the natural history, clinical features, and therapeutic requirements of late-onset seropositive and/or erosive rheumatoid arthritis (LORA). One hundred twenty-nine patients with mean disease duration of 6 years and mean age of disease onset of 66 years were studied. All patients met American Rheumatism Association criteria for rheumatoid arthritis (RA). Ninety-one percent were seropositive for rheumatoid factor, 83% had erosive disease, and 58% had significant medical problems. Therapeutically, most patients required sequential use of multiple second-line agents. Functional classification did not change significantly despite treatment, and complete remissions were unusual even with remittive therapy. It is concluded that a subset of LORA patients have seropositive aggressive, destructive disease. FAU - Lance, N J AU - Lance NJ AD - Department of Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL. FAU - Curran, J J AU - Curran JJ LA - eng PT - Journal Article PL - United States TA - Semin Arthritis Rheum JT - Seminars in arthritis and rheumatism JID - 1306053 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - Aged MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Cohort Studies MH - Female MH - Humans MH - Male MH - Methotrexate/therapeutic use MH - Middle Aged MH - Radiography MH - Retrospective Studies MH - *Still's Disease, Adult-Onset/complications/diagnostic imaging/drug therapy EDAT- 1993/12/01 00:00 MHDA- 1993/12/01 00:01 CRDT- 1993/12/01 00:00 PHST- 1993/12/01 00:00 [pubmed] PHST- 1993/12/01 00:01 [medline] PHST- 1993/12/01 00:00 [entrez] AID - S0049-0172(05)80038-1 [pii] AID - 10.1016/s0049-0172(05)80038-1 [doi] PST - ppublish SO - Semin Arthritis Rheum. 1993 Dec;23(3):177-82. doi: 10.1016/s0049-0172(05)80038-1.